公开(公告)号：US20240174683A1

公开(公告)日：2024-05-30

申请号：US18275978

申请日：2022-02-04

申请人： Bayer Aktiengesellschaft ,  Deutsches Krebsforschungszentrum

发明人： Ulrich LÜCKING ,  Jeffrey Stuart MOWAT ,  Ludwig ZORN ,  Lars WORTMANN ,  Steffen MÜLLER ,  Gabriele LEDER ,  Sandra BERNDT ,  Judith GÜNTHER ,  Lara KUHNKE ,  Antje Margret WENGNER ,  Rafael CARRETERO ,  Gerd WOHLFAHRT ,  Anders FRIBERG ,  Ulf BÖMER ,  Roland NEUHAUS ,  Maren OSMERS ,  Hideki Miyatake ONDOZABAL ,  Martina SCHÄFER ,  Louise EAGLING ,  Julien LEFRANC ,  Katrin NOWAK-REPPEL ,  Rienk OFFRINGA ,  Peng CHEN ,  Xuewei WANG ,  Yuanyuan YAN ,  Kai THEDE ,  Nikolay SITNIKOV ,  Berndt BUCHMANN ,  Dirk KOSEMUND ,  Detlef STOECKIGT

IPC分类号： C07D487/20 ,  A61K45/06 ,  C07B59/00 ,  C07D498/20

CPC分类号： C07D487/20 ,  A61K45/06 ,  C07B59/002 ,  C07D498/20 ,  C07B2200/13

摘要： The present invention relates to Map4K1 inhibitors of formula (I) (I), wherein A, E, G, Q, R1, R2 and R4 have the same meaning as defined in the description, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.